These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21241222)

  • 1. The Trans-Pacific Partnership Agreement: challenges for Australian health and medicine policies.
    Faunce TA; Townsend R
    Med J Aust; 2011 Jan; 194(2):83-6. PubMed ID: 21241222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new generation of trade policy: potential risks to diet-related health from the trans pacific partnership agreement.
    Friel S; Gleeson D; Thow AM; Labonte R; Stuckler D; Kay A; Snowdon W
    Global Health; 2013 Oct; 9():46. PubMed ID: 24131595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving trade policy and the Trans-Pacific Partnership Agreement: does it threaten Vietnam's access to medicine and its progress towards scaling up HIV prevention, treatment and care?
    Linh NN; Huong NT; Thuy HT
    Glob Public Health; 2015; 10 Supppl 1():S149-60. PubMed ID: 25469870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health.
    Labonté R; Crosbie E; Gleeson D; McNamara C
    Global Health; 2019 May; 15(1):35. PubMed ID: 31088499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA.
    Vines T; Crow K; Faunce T
    J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TPPA and tobacco control: threats to APEC countries.
    Sy DK; Stumberg RK
    Tob Control; 2014 Nov; 23(6):466-70. PubMed ID: 25170023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
    Baker BK
    PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Trans-Pacific Partnership Agreement and health: few gains, some losses, many risks.
    Labonté R; Schram A; Ruckert A
    Global Health; 2016 Jun; 12(1):25. PubMed ID: 27265351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To what extent does a tobacco carve-out protect public health in the Trans-Pacific Partnership Agreement?
    Hirono K; Gleeson D; Freeman B
    Public Health Res Pract; 2016 Apr; 26(2):. PubMed ID: 27734065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia.
    Lexchin J; Gleeson D
    Int J Health Serv; 2016 Oct; 46(4):597-613. PubMed ID: 27516183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPPA should not be adopted without a full, independent health assessment.
    Keating G; Freeman J; Macmillan A; Neuwelt P; Monasterio E
    N Z Med J; 2016 Feb; 129(1430):7-13. PubMed ID: 26914417
    [No Abstract]   [Full Text] [Related]  

  • 12. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is health impact assessment useful in the context of trade negotiations? A case study of the Trans Pacific Partnership Agreement.
    Hirono K; Haigh F; Gleeson D; Harris P; Thow AM; Friel S
    BMJ Open; 2016 Apr; 6(4):e010339. PubMed ID: 27044579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Trans-Pacific Partnership: Is It Everything We Feared for Health?
    Labonté R; Schram A; Ruckert A
    Int J Health Policy Manag; 2016 Aug; 5(8):487-496. PubMed ID: 27694662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership Agreement.
    Gleeson DH; Moir H; Lopert R
    Med J Aust; 2015 Apr; 202(6):306-8. PubMed ID: 25832153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Pacific trade deal--good for pharma, bad for public health?
    Gornall J
    BMJ; 2015 Jul; 351():h3649. PubMed ID: 26155990
    [No Abstract]   [Full Text] [Related]  

  • 18. Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review.
    Kidgell D; Hills D; Griffiths D; Endacott R
    Int J Nurs Stud; 2020 Sep; 109():103676. PubMed ID: 32603925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The high price of "free" trade: U.S. trade agreements and access to medicines.
    Lopert R; Gleeson D
    J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will the next generation of preferential trade and investment agreements undermine prevention of noncommunicable diseases? A prospective policy analysis of the Trans Pacific Partnership Agreement.
    Thow AM; Snowdon W; Labonté R; Gleeson D; Stuckler D; Hattersley L; Schram A; Kay A; Friel S
    Health Policy; 2015 Jan; 119(1):88-96. PubMed ID: 25217839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.